在多种B细胞清除抗体治疗失败后，采用靶向CD19的嵌合抗原受体T细胞（CAR-T细胞）对合成酶综合征进行挽救治疗。 - Suppr

Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.

作者信息

Taubmann Jule, Knitza Johannes, Müller Fabian, Völkl Simon, Aigner Michael, Kleyer Arnd, Gary Regina, Kretschmann Sascha, Boeltz Sebastian, Atzinger Armin, Kuwert Torsten, Roemer Frank, Uder Michael, Mackensen Andreas, Schett Georg

机构信息

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

出版信息

Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330.

DOI:10.1093/rheumatology/kead330

PMID:37432378

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10765150/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e702/10765150/7fefcfd55806/kead330f1.jpg

相似文献

Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.

Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330.

CD19-targeted CAR T cells in refractory antisynthetase syndrome.

Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15.

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.

JAMA. 2023 Jun 27;329(24):2154-2162. doi: 10.1001/jama.2023.8753.

CD19-Targeting CAR T-Cell Therapy for Antisynthetase Syndrome.

JAMA. 2023 Jun 27;329(24):2130-2131. doi: 10.1001/jama.2023.7240.

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.

[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].

Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.

Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Cancer Sci. 2017 Jun;108(6):1109-1118. doi: 10.1111/cas.13239. Epub 2017 May 25.

Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.

Rheumatology (Oxford). 2024 Nov 1;63(11):e309-e311. doi: 10.1093/rheumatology/kead668.

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.

[Development of dual-targeted CAR T-cell therapy].

Rinsho Ketsueki. 2024;65(7):662-667. doi: 10.11406/rinketsu.65.662.

引用本文的文献

[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus].

Z Rheumatol. 2025 Sep 4. doi: 10.1007/s00393-025-01705-0.

CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.

Front Immunol. 2025 Aug 13;16:1625166. doi: 10.3389/fimmu.2025.1625166. eCollection 2025.

Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.

Front Immunol. 2025 Jul 17;16:1581323. doi: 10.3389/fimmu.2025.1581323. eCollection 2025.

From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.

Clin Exp Med. 2025 Jun 6;25(1):189. doi: 10.1007/s10238-025-01717-9.

CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?

Arthritis Res Ther. 2025 May 10;27(1):102. doi: 10.1186/s13075-025-03564-1.

Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.

Front Immunol. 2025 Apr 7;16:1520063. doi: 10.3389/fimmu.2025.1520063. eCollection 2025.

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.

Nat Med. 2025 Apr 17. doi: 10.1038/s41591-025-03718-3.

Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy.

Clin Rev Allergy Immunol. 2025 Apr 10;68(1):40. doi: 10.1007/s12016-025-09047-0.

Tonic signaling in CAR-T therapy: the lever long enough to move the planet.

Front Med. 2025 Mar 21. doi: 10.1007/s11684-025-1130-x.

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.

Biomark Res. 2025 Feb 4;13(1):23. doi: 10.1186/s40364-025-00736-8.

本文引用的文献

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.

Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5.

Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.

Rheumatology (Oxford). 2023 Nov 2;62(11):3672-3679. doi: 10.1093/rheumatology/kead110.

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.

Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15.

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.

J Invest Dermatol. 2022 Oct;142(10):2651-2659.e1. doi: 10.1016/j.jid.2022.03.029. Epub 2022 Apr 29.

Idiopathic inflammatory myopathies.

Nat Rev Dis Primers. 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x.

CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.

N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725.

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.

J Clin Med. 2019 Nov 18;8(11):2013. doi: 10.3390/jcm8112013.

Treatment in myositis.

Nat Rev Rheumatol. 2018 May;14(5):279-289. doi: 10.1038/nrrheum.2018.42. Epub 2018 Mar 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献